These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25843756)

  • 1. "Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs.
    Martinelli F; Balducci AG; Rossi A; Sonvico F; Colombo P; Buttini F
    Int J Pharm; 2015 Jun; 487(1-2):197-204. PubMed ID: 25843756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
    Wauthoz N; Hennia I; Ecenarro S; Amighi K
    Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler.
    Buttini F; Pasquali I; Brambilla G; Copelli D; Alberi MD; Balducci AG; Bettini R; Sisti V
    Pharm Res; 2016 Mar; 33(3):701-15. PubMed ID: 26572643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of capsule dosing techniques for use in dry powder inhalers.
    Edwards D
    Ther Deliv; 2010 Jul; 1(1):195-201. PubMed ID: 22816126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.
    Shur J; Lee S; Adams W; Lionberger R; Tibbatts J; Price R
    AAPS J; 2012 Dec; 14(4):667-76. PubMed ID: 22723022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance.
    Faulhammer E; Wahl V; Zellnitz S; Khinast JG; Paudel A
    Int J Pharm; 2015 Aug; 491(1-2):231-42. PubMed ID: 26136200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a New Inhaler for High-Efficiency Dispersion of Spray-Dried Powders Using Computational Fluid Dynamics (CFD) Modeling.
    Longest W; Farkas D
    AAPS J; 2019 Feb; 21(2):25. PubMed ID: 30734133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.
    Farkas DR; Hindle M; Longest PW
    Ann Biomed Eng; 2015 Nov; 43(11):2804-15. PubMed ID: 25986955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the motion of hard-shell capsules in dry powder inhalers.
    Benque B; Khinast JG
    Int J Pharm; 2019 Aug; 567():118481. PubMed ID: 31260784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy.
    Buttini F; Balducci AG; Colombo G; Sonvico F; Montanari S; Pisi G; Rossi A; Colombo P; Bettini R
    Int J Pharm; 2018 Sep; 548(1):182-191. PubMed ID: 29883795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.
    Behara SR; Farkas DR; Hindle M; Longest PW
    Pharm Res; 2014 Feb; 31(2):360-72. PubMed ID: 23949304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFD-DEM investigation of the effects of aperture size for a capsule-based dry powder inhaler.
    Zhu Q; Kakhi M; Jayasundara C; Walenga R; Behara SRB; Chan HK; Yang R
    Int J Pharm; 2023 Nov; 647():123556. PubMed ID: 37890648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation.
    Buttini F; Hannon J; Saavedra K; Rossi I; Balducci AG; Smyth H; Clark A; Colombo P
    Pharm Res; 2016 Dec; 33(12):3012-3020. PubMed ID: 27623625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.